Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine.
The overproduction of nitric oxide in the small bowel has been invoked as a cytotoxic event in the vascular, mucosal, and whole organ dysfunction associated with inflammation. We assessed whether exogenous administration of nitric oxide in the form of nitric oxide donors (CAS 754, SIN-1) could cause microvascular and mucosal barrier dysfunction in vivo or epithelial and endothelial cell permeability alterations and cell injury in vitro. Increasing concentrations of CAS 754 or SIN-1 were infused locally into autoperfused segments of cat ileum at 30-min intervals. Baseline epithelial permeability (blood-to-lumen clearance of 51Cr-EDTA) was not affected by CAS 754, whereas vascular protein clearance was reduced. The latter effect could almost entirely be explained by a decrease in intestinal capillary hydrostatic pressure. Therefore, in some experiments venous pressure was elevated and the microvascular reflection coefficient for total proteins was estimated at filtration-independent rates. This direct measurement of microvascular permeability was unaffected by exogenous nitric oxide. CAS 754 did not increase permeability across monolayers of endothelial or epithelial cells and did not cause cell injury. Next, we assessed the possibility that excess nitric oxide may be detrimental, but only in inflamed intestine, by infusing CAS 754 with platelet-activating factor; the latter directly increases microvascular and mucosal permeability. CAS 754 did not exacerbate but rather reduced platelet-activating factor-induced rise in microvascular and mucosal permeability. These results suggest that high concentrations of nitric oxide do not cause breakdown of mucosal or microvascular barrier integrity under normal or inflammatory conditions.
Kubes
P
P
Department of Medical Physiology, University of Calgary Medical Center, Alberta, Canada.
Reinhardt
P H
PH
Payne
D
D
Woodman
R C
RC
D000818:Animals; D001808:Blood Vessels / Q000502:physiology; D002199:Capillary Permeability / Q000187:drug effects; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000493:pharmacokinetics; D007413:Intestinal Mucosa / Q000502:physiology*; D007421:Intestine, Small / Q000187:drug effects / Q000502:physiology*; D007422:Intestines / Q000098:blood supply*; D008981:Molsidomine / Q000031:analogs & derivatives / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D010539:Permeability / Q000187:drug effects; D010972:Platelet Activating Factor / Q000494:pharmacology; D013558:Sydnones / Q000494:pharmacology
D010972:Platelet Activating Factor; D013558:Sydnones; C072857:3-(cis-2,6-dimethylpiperidino)sydnonimine; D009569:Nitric Oxide; C002385:linsidomine; D004492:Edetic Acid; D008981:Molsidomine